Slfn11 CRISPR Activation Plasmid (h): sc-401137-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Slfn11 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Slfn11 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Slfn11 CRISPR Activation Plasmid (h) and Slfn11 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SLFN11 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Slfn11 Antibody (E-4): sc-374339
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Slfn11 CRISPR Activation Plasmid (h) | sc-401137-ACT | 20 µg | $397.00 | |||
Slfn11 CRISPR Activation Plasmid (h2) | sc-401137-ACT-2 | 20 µg | $397.00 |
Human SLFN11 (Schlafen family member 11) encodes Slfn11, an interferon-stimulated protein that links innate immune signaling to regulation of DNA replication and genome stability. Slfn11 modulates replication stress responses by influencing chromatin and replication fork progression, thereby shaping cellular outcomes following genotoxic stress and perturbations in nucleotide metabolism. SLFN11 expression and epigenetic regulation have been studied in the context of tumor biology, where altered Slfn11 activity correlates with changes in proliferative capacity and DNA damage response pathway engagement. As a result, SLFN11 is frequently investigated in mechanisms of replication stress, interferon-driven transcriptional programs, and cellular determinants of genotoxic sensitivity.
Slfn11 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLFN11 expression without altering the underlying DNA sequence.
Slfn11 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLFN11 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLFN11 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Slfn11 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLFN11 locus and enabling the study of Slfn11-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Slfn11 pathway restoration in tumor cells with silenced or reduced SLFN11 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.